DrugCite
Search

MAXIPIME

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Maxipime Adverse Events Reported to the FDA Over Time

How are Maxipime adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Maxipime, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Maxipime is flagged as the suspect drug causing the adverse event.

Most Common Maxipime Adverse Events Reported to the FDA

What are the most common Maxipime adverse events reported to the FDA?

Pyrexia
102 (1.94%)
Renal Failure Acute
88 (1.67%)
Status Epilepticus
88 (1.67%)
Confusional State
74 (1.4%)
Renal Failure
74 (1.4%)
Rash
69 (1.31%)
Encephalopathy
59 (1.12%)
Myoclonus
57 (1.08%)
Blood Creatinine Increased
54 (1.03%)
Altered State Of Consciousness
53 (1.01%)
Sepsis
53 (1.01%)
Show More Show More
Convulsion
50 (.95%)
Alanine Aminotransferase Increased
47 (.89%)
Febrile Neutropenia
47 (.89%)
Aspartate Aminotransferase Increase...
46 (.87%)
Diarrhoea
44 (.84%)
Platelet Count Decreased
44 (.84%)
Renal Impairment
43 (.82%)
Liver Disorder
41 (.78%)
Neurotoxicity
40 (.76%)
Anaemia
38 (.72%)
Aphasia
38 (.72%)
Death
38 (.72%)
Depressed Level Of Consciousness
38 (.72%)
Thrombocytopenia
37 (.7%)
Pneumonia
36 (.68%)
Interstitial Lung Disease
35 (.66%)
Stevens-johnson Syndrome
35 (.66%)
White Blood Cell Count Decreased
35 (.66%)
Blood Urea Increased
34 (.65%)
Disorientation
34 (.65%)
Hepatic Function Abnormal
34 (.65%)
Pancytopenia
34 (.65%)
Coma
32 (.61%)
Blood Alkaline Phosphatase Increase...
31 (.59%)
Dyspnoea
31 (.59%)
Multi-organ Failure
31 (.59%)
Agitation
30 (.57%)
Neutropenia
30 (.57%)
Neutrophil Count Decreased
30 (.57%)
Hypotension
29 (.55%)
Disseminated Intravascular Coagulat...
27 (.51%)
Dyskinesia
26 (.49%)
Haemoglobin Decreased
26 (.49%)
Pruritus
26 (.49%)
Tremor
26 (.49%)
Respiratory Failure
25 (.47%)
Infection
24 (.46%)
Vomiting
24 (.46%)
Blood Pressure Decreased
23 (.44%)
Gamma-glutamyltransferase Increased
23 (.44%)
Blood Bilirubin Increased
22 (.42%)
Condition Aggravated
22 (.42%)
Hypokalaemia
22 (.42%)
Toxic Epidermal Necrolysis
22 (.42%)
Acute Generalised Exanthematous Pus...
21 (.4%)
Epilepsy
21 (.4%)
Renal Disorder
21 (.4%)
Cardio-respiratory Arrest
20 (.38%)
Haematocrit Decreased
20 (.38%)
Haemodialysis
20 (.38%)
Leukopenia
20 (.38%)
Mental Status Changes
20 (.38%)
Nausea
20 (.38%)
White Blood Cell Count Increased
20 (.38%)
Blood Lactate Dehydrogenase Increas...
19 (.36%)
Pleural Effusion
19 (.36%)
Drug Rash With Eosinophilia And Sys...
18 (.34%)
Gastrointestinal Haemorrhage
18 (.34%)
Lethargy
18 (.34%)
Renal Tubular Necrosis
18 (.34%)
Atrial Fibrillation
17 (.32%)
Clostridium Difficile Colitis
17 (.32%)
Decreased Appetite
17 (.32%)
Dehydration
17 (.32%)
Somnolence
17 (.32%)
Anaphylactic Shock
16 (.3%)
Asthenia
16 (.3%)
Haematuria
16 (.3%)
Hallucination
16 (.3%)
Septic Shock
16 (.3%)
Unresponsive To Stimuli
16 (.3%)
Urine Output Decreased
16 (.3%)
C-reactive Protein Increased
15 (.28%)
Cholestasis
15 (.28%)
Drug Interaction
15 (.28%)
Loss Of Consciousness
15 (.28%)
Malaise
15 (.28%)
Oliguria
15 (.28%)
Overdose
15 (.28%)
Disease Progression
14 (.27%)
Hypertension
14 (.27%)
Speech Disorder
14 (.27%)
Headache
13 (.25%)
Red Blood Cell Count Decreased
13 (.25%)
Tubulointerstitial Nephritis
13 (.25%)
Bronchopulmonary Aspergillosis
12 (.23%)
Clostridial Infection
12 (.23%)
Dialysis
12 (.23%)
Drug Hypersensitivity
12 (.23%)
Drug Ineffective
12 (.23%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Maxipime, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Maxipime is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Maxipime

What are the most common Maxipime adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Maxipime, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Maxipime is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Maxipime According to Those Reporting Adverse Events

Why are people taking Maxipime, according to those reporting adverse events to the FDA?

Pneumonia
223
Febrile Neutropenia
178
Drug Use For Unknown Indication
161
Product Used For Unknown Indication
156
Infection
140
Pyrexia
114
Show More Show More
Infection Prophylaxis
99
Sepsis
86
Prophylaxis
79
Urinary Tract Infection
51
Osteomyelitis
44
Pseudomonas Infection
40
Antibiotic Prophylaxis
30
Lung Infection
20
Bacterial Infection
19
Neutropenia
18
Bacteraemia
18
Pneumonia Aspiration
17
Cellulitis
16
Pneumonia Bacterial
14
Respiratory Tract Infection
14
Antibiotic Therapy
13
Evidence Based Treatment
12
Wound Infection
11
Bronchitis
11
Lung Infection Pseudomonal
10
Bronchopneumonia
10
Cholangitis
9
Device Related Infection
9
Pyelonephritis
8
Escherichia Infection
8
Pharyngitis
8
Cystic Fibrosis
8
Urosepsis
7
Acute Myeloid Leukaemia
7
Ill-defined Disorder
6
C-reactive Protein Increased
6
Multiple Myeloma
6
Post Procedural Infection
6
Klebsiella Infection
6
Skin Infection
6
Anti-infective Therapy
5
Endocarditis
5
Septic Shock
5
Bronchopulmonary Aspergillosis
5
Bronchiectasis
5
Abdominal Infection
5
Interstitial Lung Disease
5
Diabetic Foot
5
Streptococcal Infection
5
Catheter Related Infection
4

Drug Labels

LabelLabelerEffective
MaxipimeElan Pharmaceuticals, Inc.01-AUG-10
MaxipimeCardinal Health26-MAY-11
MaxipimeHospira, Inc.07-JAN-13

Maxipime Case Reports

What Maxipime safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Maxipime. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Maxipime.